Generic Name:
Atezolizumab
Project Status:
Complete
Therapeutic Area:
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0115-000
NOC Date:
Details
Strength:
60 mg/mL
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on or after systemic chemotherapy until loss of clinical benefit
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued: